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We identiﬁ  ed 2 cases of European bat lyssavirus sub-
type 1 transmission to domestic carnivores (cats) in France. 
Bat-to-cat transmission is suspected. Low amounts of virus 
antigen in cat brain made diagnosis difﬁ  cult.
M
ost countries in western Europe are currently free 
of rabies in terrestrial mammals, as was the case in 
France during 2001–2008 (1). However, rabies still remains 
a public health problem in these countries because of natural 
circulation of bat-speciﬁ  c viruses (order Mononegavirales, 
family Rhabdoviridae, genus Lyssavirus) such as European 
bat lyssaviruses (EBLVs). These viruses are divided into 
genotypes 5 (EBLV-1) and 6 (EBLV-2); the ﬁ  rst genotype 
is subdivided into subtypes a and b (2). Knowledge of the 
prevalence and epidemiology of EBLV is limited (2–5). To 
date, natural transmission of EBLV-1 has been reported in 
a limited number of terrestrial mammals, including 5 sheep 
in Denmark (6) and 1 stone marten in Germany (7) (Table 
1). Since 1985, only 3 human deaths from EBLVs have 
been conﬁ  rmed (3) (Table 1). We describe 2 documented 
cases of spillover transmission of EBLV in domestic carni-
vores (cats, Felis domesticus) in Europe.
The Study
In November 2003, a 6-month-old female stray cat (cat 
no. 1) was found ill in a public garden in Vannes (Morbihan 
District) in western France and taken to a veterinary clinic. 
This animal had convulsions and moderate dehydration and 
was emaciated. It was infected by feline immunodeﬁ  ciency 
virus, which was compatible with the clinical symptoms. 
The veterinarian was bitten while providing veterinary care 
to the cat. After a few days, the cat recovered and was im-
pounded for veterinary surveillance. It died suddenly the 
following night. No information about potential contact 
with bats was available.
On November 8, 2007, an 18-month-old female cat (cat 
no. 2) was taken by its owner to a veterinarian in Fontenay-
le-Comte (Vendée District) in western France because of 
abnormal behavior. The owner reported having been bitten 
by the cat. The next day, the cat showed severe central neu-
rologic disorders and aggressive behavior. It died during 
the next night. Its outdoor access appeared to have been 
restricted. Two months later, the carcass of a bat (Eptesicus 
serotinus) was recovered in the same area of Fontenay-le-
Comte and submitted for rabies testing.
Recommended techniques for rabies diagnosis were 
used for all animals (8). For cat no. 1, results of a repeat-
ed direct immunoﬂ  uorescence antibody test (FAT) with a 
polyclonal antirabies conjugate (Bio-Rad, Marnes-la-Co-
quette, France) performed on different cortex and spinal 
bulb smears were negative. Viral isolation by using a rabies 
tissue culture infection test (RTCIT) was also unsuccess-
ful, as was attempted isolation of virus by using a mouse 
inoculation test (MIT) (Table 1). The only test routinely 
used that gave a positive result was an antigen-capture 
ELISA (WELYSSA) for lyssavirus antigen (9). The pres-
ence of EBLV RNA (03011FRA) was determined by reverse 
transcription–PCR (RT-PCR) targeting short viral gene 
regions (5).
Lyssavirus antigens were repeatedly detected by FAT 
in different areas of the brain of cat no. 2. Viral isolation by 
using RTCIT was positive only after the second cell culture 
passage. Results for isolation of EBLV (07240FRA) by 
MIT were positive. Lyssavirus antigen detection by WEL-
YSSA was variable, depending on the part of the brain 
tested. Viral RNA was detected by RT-PCR (Table 1). The 
bat was positive for EBLV by FAT, RTCIT (08120FRA), 
MIT, and RT-PCR.
Nucleotide sequencing and phylogenetic analysis 
identiﬁ   ed isolate 03011FRA as EBLV-1b and isolates 
08120FRA and 07240FRA as EBLV-1a (Figure 1). Se-
quencing of the complete genome (10) of the 2 EBLV-1a 
isolates showed a high percentage of homology (Table 2).
After identiﬁ  cation of these 2 cases of spillover trans-
mission of EBLV-1 to domestic cats, postexposure prophy-
laxis measures were implemented. The veterinarian who 
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was bitten by cat no. 1 received a booster rabies vaccina-
tion, and 15 persons exposed to cat no. 2 during the 2-week 
critical period before its death received appropriate postex-
posure treatment on the basis of national and international 
recommendations of the World Health Organization (8,11). 
Two family dogs potentially exposed to cat no. 2 and pre-
viously vaccinated received a booster vaccination. Cross-
neutralization data obtained with human serum samples 
and in rodent models suggest that preexposure and postex-
posure treatments for rabies are effective against EBLV-1.
Control measures were implemented to prevent poten-
tial further contaminations, although cats represent natu-
rally dead-end host for rabies (and for lyssavirus), thereby 
limiting any risk for transmission to other mammals. City 
authorities conducted a census of all domestic animals in 
the neighborhood where cat no. 2 lived. All cats, dogs, and 
ferrets were identiﬁ  ed by microchips and kept under vet-
erinary surveillance. Dogs had to be leashed and cats kept 
indoors during the next 2 months.
Conclusions
We report 2 documented cases of natural infection of 
domestic cats by EBLV-1 lyssaviruses presently circulat-
ing in European bats (2–5). Our study demonstrates that 
subtypes EBLV-1a and EBLV-1b can cross the species 
barrier, although cat no. 1 probably died of feline leukemia. 
However, cat no. 2 died with neurologic signs compatible 
with rabies and was positive for EBLV by FAT, the refer-
ence technique. Direct transmission of EBLV-1 from bats 
to cats seems the most realistic explanation for these cas-
es because cats prey on bats and have numerous contacts 
with them (3,12,13). Identiﬁ  cation of a highly homologous 
EBLV-1a isolate from a rabid bat found in the same loca-
tion as cat no. 2 supports this hypothesis.
Difﬁ  culties in EBLV-1 detection in the brain of these 2 
cases of spillover transmission are reminiscent of transmis-
sion previously reported (6,7) (Table 1), potentially caused 
by a low amount of virus antigen in the brain. This ﬁ  nding 
further underlines the importance of using different tech-
niques to diagnose rabies caused by EBLVs (9). This issue 
raises questions about the true incidence of these viruses 
among cats.
At the Institut Pasteur during 1997–2007, a total of 
6,097 cats suspected of having rabies and originating from 
all districts in France showed negative results for rabies 
by 2 recommended techniques (FAT and RTCIT). Among 
them, all animals tested since 2004 (1,506 cats), except cats 
no. 1 and no. 2, were also negative for rabies by WELYS-
SA (Figure 2), which suggests that transmission of EBLVs 
from bats to cats, although possible, is rare. Furthermore, 
terrestrial mammals seem to represent dead-end hosts for 
EBLVs, as suggested by results of experimental EBLV 
inoculations in several mammals such as cats, dogs, fer-
rets, mice, red foxes, or sheep (6,7,14). These animals are 
susceptible to infection with EBLVs but seem unlikely to 
actively transmit EBLVs to a new host.
Comparative analysis of the full-length genomic se-
quence of the EBLV-1a from cat no. 2 isolate 07240FRA 
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Table 1. Confirmed cases of EBLV spillover transmission to terrestrial mammals and humans, Europe* 
Techniques used for rabies diagnosis on original brain 
samples




or disease  FAT RTCIT MIT ELISA RT-PCR 
EBLV
type  




+ (weak)  + (1 of 4 
sheep)










+ (weak)  + ND + 1a




++ – N D N D 1 a
Domestic cat§ (1), 










– (after 3 cell 
culture
passages)
–+ + 1 b
Domestic cat§ (1), 













Man, 30 y of age 
(1)
1985 Helsinki, Finland  Rabies + + + ND ND 2
Girl, 11 y of age (1)  1985 Belgorod,
Russia
Rabies – ND + ND ND 1a
Man, 55 y of age 
(1)
2002 Angus, Scotland  Rabies + + + ND + 2
*EBLV, European bat lyssavirus; FAT, direct immunofluorescence antibody test; RTCIT, rabies tissue culture infection test; MIT, mouse inoculation test; 
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Figure 1. Phylogenetic tree comparing nucleotide sequences of A) nucleoprotein (372 nt, position 63 from the translation initiation site) 
and B) glycoprotein (547 nt, position 640 from the translation initiation site) genes of spillover transmission of European bat lyssavirus-1 
(EBLV-1) in terrestrial mammals and human with representative isolates of the diversity of EBLV-1 in Europe. Cases described in this 
report are indicated by the arrows. For each dataset, we inferred a maximum clade credibility phylogenetic tree by using the Bayesian 
Markov Chain Monte Carlo method available in the Bayesian Evolutionary Analysis Sampling Trees software (http://beast.bio.ed.ac.uk). 
This analysis used a relaxed (uncorrelated lognormal) molecular clock and the HKY85 + Γ4 model of nucleotide substitution. All horizontal 
branches are scaled according to the number of substitutions per site. Bootstrap values are indicated at the nodes. All GenBank accession 
numbers corresponding to full-length or partial nucleoprotein and glycoprotein nucleotide sequences were previously described (2,10) 
except for nucleoprotein nucleotide sequences of isolates 03011FRA (EU636795), 04032FRA (EU636794), 05001FRA (EU636790), 
05002FRA (EU636789), 06001FRA (EU636791), 06002FRA (EU636792), and 070057FRA (EU636793) and glycoprotein nucleotide 
sequences of isolates 03011FRA (EU636787) and 04032FRA (EU636788).
Table 2. Percentage nucleotide divergence between EBLV-1a strains isolated from a cat (07240FRA) and bats (08120FRA, 
03002FRA, and RV9)* 
Strain
Gene Sequence 07240FRA/08120FRA 07240FRA/03002FRA 07240FRA/RV9
Complete genome nt 0.1 (12) 0.4 (36) 2 (226)
nt 0 0.2 (2) 1.5 (19) Nucleoprotein
aa 0 0 0
nt 0.1 (1) 0.4 (4) 2.3 (23) Phosphoprotein
aa 0.3 (1), I149T 0.7 (2), I149T, G175D 1.7 (7), Q147R, I149T, T156A,
F169S, P174L, G175D, G266S
nt 0 0.3 (2) 1.5 (7) Matrix
aa 0 0 1 (2), N2K, I155M
nt 0 0.2 (3) 2.1 (32) Glycoprotein
aa 0 0.2 (1), S489P 0.8 (4), L244Q, S278N, S489P,
A521T
nt 0.03 (2) 0.3 (16) 1.9 (109) Polymerase
aa 0 0.2 (4), A97T, G1160D, T1754I,
R1894S
0.3 (5), R315K, I391V, K980R,
T1754I, R1894S
*Strains 07240FRA and 08120FRA were isolated from cat no. 2 and from a bat (Eptesicus serotinus) found dead in the same area (Fontenay-le-Comte, 
France), respectively. Strain 03002FRA was isolated from another bat (E. serotinus) collected |100 km from Fontenay-le-Comte in 2003 (10). Isolate RV9 
was collected from a bat (E. serotinus) in 1968 in Germany (15). Numbers of substitutions are indicated in parentheses. Type of amino acid substitutions 
are indicated in boldface. GenBank accession numbers for full-length genomic sequences corresponding to strains 07240FRA, 08120FRA, 03002FRA, 
and RV9 are EU626552, EU626551, EU293109, and EF157976, respectively. EBLV, European bat lyssavirus; nt, nucleotide; aa, amino acid.European Bat Lyssavirus Transmission among Cats
with bat isolate 08120FRA and with another bat (E. seroti-
nus) isolate (03002FRA) collected in 2003 ≈100 km from 
Fontenay-le-Comte showed high similarity (Table 2). This 
ﬁ  nding indicates that heterologous passage of EBLV-1a in 
a cat did not select mutants. Similarly, the lower similar-
ity observed with a genomic sequence collected from a bat 
RV9 (15) (E. serotinus) in 1968 in Germany also indicates 
that EBLV-1 evolution is shaped by slow genetic drift (2).
No secondary cases originating from cat no. 1 and cat 
no. 2 were reported (after 6 months of follow-up for cat no. 
2). However, improving surveillance and raising awareness 
to better understand the epidemiology of lyssaviruses are 
necessary. Persons bitten by bats or by any carnivorous ani-
mal are advised to wash wounds with water and soap and to 
seek medical attention (8,11).
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